ADCs Target Cancer, Reduce Side Effects

ADCs or Antibody-Drug Conjugates are a breakthrough in cancer treatment technology. They combine the precision of monoclonal antibodies with the powerful effects of chemotherapy, aiming to kill cancer cells with minimal harm to healthy tissue.

What Are ADCs?

ADCs are made by attaching a monoclonal antibody (that specifically targets cancer cell proteins) to a potent chemotherapy drug via a chemical linker. This allows the drug to be released only inside the cancer cell, improving precision and minimizing side effects.

How Do ADCs Work?

Targeting: The antibody part of the ADC binds to a protein found specifically on the surface of cancer cells.
Internalization: Once bound, the entire ADC is absorbed into the cancer cell.
Drug Release: The linker breaks down inside the cell, releasing the toxic drug that kills the cancer cell from within.

Advantages of ADCs

Highly targeted therapy to cancer cells
Fewer side effects compared to conventional chemotherapy
Effective in patients who are resistant to standard treatments
Applicable to several types of cancer, such as breast cancer, lung cancer, and certain lymphomas

Are ADCs Used in Real Treatments?

Several ADCs have already been approved by the FDA, including:

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Brentuximab vedotin for lymphoma
Many others are in clinical trials for various types of cancer

Conclusion: Targeted, Effective, and Safer

ADCs represent a promising approach to treating cancer with greater accuracy and fewer side effects. If you’re exploring new treatment options, talk to an oncologist to see whether ADCs could be right for you.